HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through its ambulatory ECG signal platform, announced it will host a conference call on Aug. 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide strategic updates. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, with a question-and-answer session following prepared remarks.
The announcement comes as HeartBeam advances its proprietary platform technology, which the company describes as the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This innovation is designed for portable use outside medical facilities, enabling physicians to detect cardiac health trends and acute conditions and direct patients to appropriate care. The platform received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, according to the company's cleared indications for use available at https://www.heartbeam.com/indications.
The upcoming call will focus on the company's strategy to accelerate global adoption of this technology, which holds over 20 issued patents. HeartBeam's approach addresses a critical need in cardiac care: enabling diagnosis and monitoring outside hospital settings. The ability to synthesize a 12-lead ECG from a compact, cable-free device could significantly improve access to cardiac monitoring, particularly for patients in remote areas or those requiring long-term surveillance. The company's technology is positioned to redefine cardiac health management by delivering actionable heart intelligence wherever the patient is.
Investors and stakeholders can access the full press release for more details at https://ibn.fm/sqGLs. The call will provide insights into the company's financial performance and strategic milestones, including progress in regulatory approvals, commercialization efforts, and partnerships. As HeartBeam continues to build on its FDA clearances, the market will be watching for updates on adoption rates, reimbursement pathways, and competitive positioning.
The importance of this announcement lies in HeartBeam's potential to disrupt the traditional ECG market. Current standard-of-care devices often require patients to visit clinics or wear bulky Holter monitors, limiting data collection to short periods. HeartBeam's platform promises continuous, high-quality cardiac monitoring in a form factor that patients can use daily. With cardiac conditions remaining a leading cause of death globally, innovations that improve early detection and ongoing management are critical. The company's strategy to drive global adoption could transform how physicians diagnose arrhythmias and other cardiac events, potentially reducing hospitalizations and improving outcomes.
HeartBeam's financial results for the second quarter will offer a window into the company's revenue growth, cash position, and spending on R&D and commercialization. As a pre-revenue or early-revenue company, investors will be keen to assess progress against milestones and the timeline to profitability. The Q2 2026 call will thus serve as a key indicator of the company's trajectory in the rapidly evolving digital health and cardiac monitoring market.
